Rosalind Advisors Inc. Buys Shares of 76,685 Vor Biopharma Inc. (NYSE:VOR)

Rosalind Advisors Inc. purchased a new stake in shares of Vor Biopharma Inc. (NYSE:VOR) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 76,685 shares of the company’s stock, valued at approximately $54,000. Vor Biopharma makes up approximately 0.0% of Rosalind Advisors Inc.’s portfolio, making the stock its 29th largest position. Rosalind Advisors Inc. owned 0.11% of Vor Biopharma as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its position in Vor Biopharma by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after acquiring an additional 69,436 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Vor Biopharma by 48.0% during the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after purchasing an additional 160,642 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after purchasing an additional 48,017 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock valued at $79,000 after purchasing an additional 27,597 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vor Biopharma in the 2nd quarter valued at $63,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Stock Performance

Shares of NYSE:VOR opened at $0.78 on Wednesday. The business has a 50 day moving average price of $0.80 and a 200 day moving average price of $1.09. Vor Biopharma Inc. has a twelve month low of $0.63 and a twelve month high of $3.14.

Vor Biopharma (NYSE:VOR) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, hitting analysts’ consensus estimates of ($0.41). Research analysts forecast that Vor Biopharma Inc. will post -1.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on VOR. HC Wainwright restated a “buy” rating and set a $17.50 target price on shares of Vor Biopharma in a report on Friday, September 6th. JMP Securities restated a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a report on Friday, September 6th. Finally, Barclays decreased their target price on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $10.92.

Vor Biopharma Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.